ALX Oncology Falls After Updated Data For Solid Tumors Candidate

  • ALX Oncology Holdings Inc ALXO released additional data from a phase 1b trial of evorpacept in solid tumor malignancies.
  • One cohort included gastric/gastroesophageal junction cancer patients receiving evorpacept plus Roche Holdings AG's RHHBY Herceptin (trastuzumab), plus chemotherapy.
  • Results showed an initial objective response rate (ORR) of 72.2% with a median duration of response (mDOR) of 14.8 months, a 12-month overall survival (OS) rate of 79%, and median overall survival (mOS) of 17.1 months.
  • The Company also shared data from a second cohort of head and neck squamous cell carcinoma patients receiving evorpacept plus Merck & Co Inc's MRK Keytruda (pembrolizumab) with and without chemotherapy.
  • In patients who did not receive prior treatment, evorpacept had an initial ORR of 38.5% with a 12-month OS rate of 87.5%. mOS was not reached in combination with pembrolizumab + 5FU + platinum.
  • Preliminary data suggest that evorpacept is well tolerated with no maximum tolerated dose reached.
  • Price Action: ALXO shares are down 23.5% at $39.86 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsPhase 1 TrialSolid Tumor
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!